Brought to you by 
Merck, Pfizer team up on Phase III trials and future commercialization of Pfizer's SGLT2 inhibitor for Type II diabetes
31 May 2013
Executive Summary
Merck & Co. Inc. and Pfizer Inc. have entered into a worldwide (excluding Japan) collaboration surrounding the development and commercialization of Pfizer’s oral sodium-dependent glucose cotransporter (SGLT2) inhibitor ertugliflozin (PF04971729), which will enter Phase III trials for Type II diabetes later this year.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck, Pfizer team up on Phase III trials and future commercialization of Pfizer's SGLT2 inhibitor for Type II diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice